Alterola Biotech (ABTI) 10-Q/A20 Feb 242024 Q3 Quarterly report (amended)Financial data

Company Profile

Cover

Cover - shares	9 Months Ended
Cover - shares	Dec. 31, 2023	Feb. 18, 2024
Cover [Abstract]
Document Type	10-Q/A
Amendment Flag	true
Amendment Description	Include iXBRL
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2023
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--03-31
Entity File Number	333-156091
Entity Registrant Name	Alterola Biotech, Inc.
Entity Central Index Key	0001442999
Entity Tax Identification Number	82-1317032
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	47 Hamilton Square
Entity Address, City or Town	Birkenhead Merseyside
Entity Address, Country	GB
Entity Address, Postal Zip Code	CH41 5AR
City Area Code	151
Local Phone Number	601 9477
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		1,382,662,952
[custom:CountryAreaCode]	+44

UNAUDITED CONSOLIDATED BALANCE

UNAUDITED CONSOLIDATED BALANCE SHEETS - USD ($)	Dec. 31, 2023	Mar. 31, 2023
Current Assets
Bank	$ 2,574	$ 8,890
VAT receivable		37,953
Deferred tax asset		189,355
Inventories	1,015	986
Total Current Assets	3,589	237,184
Intangible assets		12,139,779
TOTAL ASSETS	3,589	12,376,963
Current Liabilities
Accounts payable	803,841	611,805
Accrued expenses	310,522	254,864
Loan payable, related party	244,061	1,260,434
Total Current Liabilities	1,358,424	2,127,103
Convertible Note Payable		154,313
Total Liabilities	1,358,424	2,281,416
Stockholders’ Equity (Deficit)
Preferred Stock, $0.001 par value, 10,000,000 shares authorized, -0- shares issued and outstanding
Common Stock, $0.001 par value, 2,000,000,000 shares authorized, 1,382,662,952 and 807,047,948 shares issued and outstanding, respectively	1,382,663	807,048
Additional paid-in capital	9,663,971	18,927,919
Accumulated deficit	(12,441,456)	(9,576,247)
Foreign currency translation adjustment	10,971	(63,173)
Total Stockholders’ Equity (Deficit)	(1,354,835)	10,095,547
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	$ 3,589	$ 12,376,963

UNAUDITED CONSOLIDATED BALANC_2

UNAUDITED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Dec. 31, 2023	Mar. 31, 2023	Dec. 31, 2022	Mar. 31, 2022
Statement of Financial Position [Abstract]
Preferred Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	10,000,000	10,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Common Stock, Shares Authorized	2,000,000,000	2,000,000,000
Common Stock, Shares, Issued	1,382,662,952	807,047,948	807,047,948	802,913,333
Common Stock, Shares, Outstanding	1,382,662,952	807,047,948	807,047,948	802,913,333

UNAUDITED CONSOLIDATED STATEMEN

UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		9 Months Ended
UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
REVENUES
OPERATING EXPENSES
Accounting and audit fees	27,882	19,001	99,982	86,816
Professional fees	273,659	249,183	280,844	363,193
Research and development	2,880		2,880	41,086
Legal fees	60,939	166,699	73,838	174,728
Directors fees and expenses	31,575	27,931	227,575	546,571
Consulting fees	661,421	198,335	995,099	481,429
Salaries and wages	26,857	(92,638)	96,315	101,238
General and administrative expenses	23,734	(27,890)	49,138	28,931
TOTAL OPERATING EXPENSES	1,108,947	540,621	1,825,671	1,823,992
LOSS FROM OPERATIONS	(1,108,947)	(540,621)	(1,825,671)	(1,823,992)
OTHER INCOME (EXPENSE)
Income tax expense for valuation allowance on deferred tax asset	(194,800)		(194,800)
Loss on impairment of intangible assets	(300,000)		(300,000)
Gain (loss) on conversion of note	(406,575)		(544,738)
TOTAL OTHER INCOME (EXPENSE)	(901,375)		(1,039,538)
PROVISION FOR INCOME TAXES		(5,832)		101,301
NET LOSS	(2,010,322)	(534,789)	(2,865,209)	(1,722,691)
Foreign exchange translation gain (loss)	(9,650)	25,730	74,144	43,152
Comprehensive loss	$ (2,019,972)	$ (509,059)	$ (2,791,065)	$ (1,679,539)
NET LOSS PER SHARE: BASIC AND DILUTED	$ 0	$ 0	$ 0	$ 0
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING: BASIC AND DILUTED	1,265,220,104	807,047,948	948,110,596	806,766,837

UNAUDITED CONSOLIDATED STATEM_2

UNAUDITED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)	Common Stock [Member]	Treasury Stock, Common [Member]	Additional Paid-in Capital [Member]	Stock Subscription [Member]	Comprehensive Income [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Mar. 31, 2022	$ 802,633		$ 17,942,833	$ 136,721	$ 14,599	$ (7,833,790)	$ 11,062,996
Shares, Issued at Mar. 31, 2022	802,633,333
Foreign currency translation					43,152		43,152
Shares issued for cash	$ 280		136,721	(136,721)			280
[custom:StockIssuedDuringPeriodSharesForCash]	280,000
Shares issued for cash	$ 385		49,615				50,000
Stock Issued During Period, Shares, New Issues	384,615
Shares issued for services	$ 1,500		319,500				321,000
Stock Issued During Period, Shares, Issued for Services	1,500,000
Shares issued for services- directors	$ 2,250		479,250				481,500
Stock Issued During Period, Shares, Employee Benefit Plan	2,250,000
Net loss						(1,722,691)	(1,722,691)
Ending balance, value at Dec. 31, 2022	$ 807,048		18,927,919		57,751	(9,556,481)	10,236,237
Shares, Issued at Dec. 31, 2022	807,047,948
Beginning balance, value at Mar. 31, 2023	$ 807,048		18,927,919		(63,173)	(9,576,247)	10,095,547
Shares, Issued at Mar. 31, 2023	807,047,948
Foreign currency translation					74,144		74,144
Shares issued for services	$ 16,088	$ (16,088)	305,672				305,672
Stock Issued During Period, Shares, Issued for Services	16,088,000	(16,088,000)
Shares issued for services- directors	$ 9,000	$ (9,000)	171,000				171,000
Stock Issued During Period, Shares, Employee Benefit Plan	9,000,000	(9,000,000)
Net loss						(2,865,209)	(2,865,209)
Shares reclaimed into treasury shares	$ (44,064)	$ 44,064
Stock Issued During Period, Shares, Treasury Stock Reissued	(44,064,000)	44,064,000
Shares issued for warrants	$ 13,500	$ (13,500)
Stock Issued During Period, Shares, Conversion of Convertible Securities	13,500,000	(13,500,000)
Shares issued for acquisition of Alinova Resources	$ 5,000	$ (5,000)	295,000				295,000
Stock Issued During Period, Shares, Acquisitions	5,000,000	(5,000,000)
Shares issued for settlement of debt	$ 476	$ (476)	157,339				157,339
Stock Issued During Period, Shares, Other	476,000	(476,000)
Shares reclaimed from asset sale	$ (24,000)	$ 24,000	(12,000,000)				(12,000,000)
[custom:StockReclaimedDuringPeriodSharesAcquisitionCancellation]	(24,000,000)	24,000,000
Additional shares reclaimed from asset sale	$ (5,016)	$ 5,016
[custom:StockReclaimedAdditionalDuringPeriodSharesAcquisitionCancellation]	(5,015,993)	5,015,993
Shares issued for conversion of debt	$ 587,500		1,762,500				2,350,000
[custom:StockIssuedDuringPeriodSharesConversionOfDebt]	587,499,996
Shares issued for outside services	$ 8,360		21,737				30,097
[custom:StockIssuedDuringPeriodSharesOutsideServices]	8,360,306
Shares issued for services – internal	$ 8,771		22,804				31,575
[custom:StockIssuedDuringPeriodSharesInternalServices]	8,770,695
Ending balance, value at Dec. 31, 2023	$ 1,382,663	$ 29,016	$ 9,663,971		$ 10,971	$ (12,441,456)	$ (1,354,835)
Shares, Issued at Dec. 31, 2023	1,382,662,952	29,015,996

UNAUDITED CONSOLIDATED STATEM_3

UNAUDITED CONSOLIDATED STATEMENT OF CASH FLOWS - USD ($)	9 Months Ended
UNAUDITED CONSOLIDATED STATEMENT OF CASH FLOWS - USD ($)	Dec. 31, 2023	Dec. 31, 2022
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss for the period	$ (2,865,209)	$ (1,722,691)
Adjustments to reconcile net loss to net cash flows used in operating activities
Non cash currency adjustments
Stock for services		802,500
Stock to directors
Income tax expense for valuation allowance on deferred tax asset	189,355
Impairment of intangibles	439,779
Shares issued for warrants
Stock subscriptions delivered		136,721
Changes in assets and liabilities:
Funds in attorney trust		12,409
Inventory
VAT receivable	66,637	15,308
Deferred tax asset		(142,850)
Accounts payable	740,284	126,162
Accrued liabilities	55,658	(384,057)
Net Cash Used by Operating Activities	(1,373,496)	(1,156,498)
CASH FLOWS FROM INVESTING ACTIVITIES
Acquisition of intangible assets		(18,147)
Net Cash (Used) Provided by Investing Activities		(18,147)
CASH FLOWS FROM FINANCING ACTIVITIES
Purchase of common shares for cash	(44,064)	50,280
Shares issued for conversion of debt to equity	544,738
Loan from related parties	788,889	1,043,125
Net Cash Provided by Financing Activities	1,289,563	1,093,405
Net change in cash	(83,933)	(81,240)
Effect of exchange rate adjustments on cash	77,617	30,240
Cash and cash equivalents, beginning of period	8,890	63,816
Cash and cash equivalents, end of period	2,574	12,816
NON-CASH INVESTING AND FINANCING INFORMATION
Shares issued for services	335,769	802,500
Shares issued to directors	202,575
Shares issued for asset acquisition	295,000
Shares issued for conversion of notes payable	$ 2,507,339

NOTE 1 _ NATURE OF BUSINESS, LI

NOTE 1 – NATURE OF BUSINESS, LIQUIDITY & GOING CONCERN	9 Months Ended
NOTE 1 – NATURE OF BUSINESS, LIQUIDITY & GOING CONCERN	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
NOTE 1 – NATURE OF BUSINESS, LIQUIDITY & GOING CONCERN	NOTE 1 – NATURE OF BUSINESS, LIQUIDITY & GOING CONCERN After formation, the Company was in the business of mineral exploration. On May 3, 2010, the Company sold its mineral exploration business and entered into an Intellectual Property Assignment Agreement (“IP Agreement”) with Soren Nielsen pursuant to which Mr. Nielsen transferred his right, title and interest in all intellectual property relating to certain chewing gum compositions having appetite suppressant activity (the “IP”) to the Company for the issuance of 55,000,000 Following the acquisition of the IP the Company changed its business direction to pursue the development of chewing gums for the delivery of Nutraceutical/functional ingredients for applications such as appetite suppressant, cholesterol suppressant, vitamin delivery, antioxidant delivery and motion sickness suppressant. On January 19, 2021, the Company entered into an Stock Purchase Agreement (the “Agreement”) with ABTI Pharma Limited, a company registered in England and Wales (“ABTI Pharma”), pursuant to which the Company agreed to acquire all of the outstanding shares of capital stock of ABTI Pharma from its shareholders in exchange for 600,000,000 The transaction was accounted for as a reverse acquisition and recapitalization. ABTI Pharma is the acquirer for accounting purposes and the Company is the issuer. The historical financial statements presented are the financial statements of ABTI. The Agreement was treated as a recapitalization and not as a business combination; at the date of the acquisition, the net liabilities of the legal acquirer, Alterola, were $389,721 The business plan of the company isl no longer focused on a chewing gum delivery system but was re-focused on the development of cannabinoid, cannabinoid-like, and non-cannabinoid pharmaceutical active pharmaceutical ingredients (APIs), pharmaceutical medicines made from cannabinoid, cannabinoid-like, and non-cannabinoid APIs and European novel food approval of cannabinoid-based, cannabinoid-like and non-cannabinoid ingredients and products .In addition, the company plans to develop such bulk ingredients for supply into the cosmetic sector. On December 2, 2021, the Company closed an Asset Purchase Agreement (the “Purchase Agreement”) with C2 Wellness Corp., a Wyoming corporation, and Dr. G. Sridhar Prasad (together, the “Seller”) and acquired certain IP assets (the “Assets”) from Seller, which include: • Novel cannabinoid molecules and their associated intellectual property; • Novel cannabinoid pro-drugs, and their associated intellectual property; • Novel proprietary cannabinoid formulations, designed to target lymphatic delivery, and their associated intellectual property; • Novel proprietary nano-encapsulated cannabinoid formulations, in self-dissolving polymers, and their associated intellectual property; and • Cannabinoids and cannabinoid pro-drug formulations for topical ocular delivery, and their associated intellectual property. In exchange for the Assets, the Company issued to Seller shares of common stock. On September 8, 2023, the Company and Seller entered into an Agreement to sell the assets, such that the Company sold the assets back to the Seller and the Seller paid 29,015,993 shares of ABTI common stock to the Company. The assets were sold to the Seller in September 2023. As of July 5, 2023, we acquired intellectual property from Alinova Biosciences Ltd. We acquired Alinova’s joint interest in the patent family of PTX 0001. We paid 35,000 5,000,000 ALTEROLA BIOTECH, INC. NOTES TO THE UNAUDITED CONSOIDATED FINANCIAL STATEMENTS DECEMBER 31, 2023 LIQUIDITY & GOING CONCERN Alterola has negative working capital of $1,160,035 $11,946,656 The ability of Alterola to continue as a going concern is dependent on the Company generating cash from the sale of its common stock and/or obtaining debt financing and attaining future profitable operations. Management’s plans include selling its equity securities and obtaining debt financing to fund its capital requirement and ongoing operations; however, there can be no assurance the Company will be successful in these efforts.

NOTE 2 _ SUMMARY OF SIGNIFICANT

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	Dec. 31, 2023
Accounting Policies [Abstract]
NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation These unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”). They include the accounts of Alterola and its wholly owned subsidiaries ABTI Pharma, Phytotherapeutix Ltd and Ferven Ltd.. All material intercompany transactions and balances have been eliminated. These financial statements and the notes attached hereto should be read in conjunction with the financial statements and notes included in the Company’s 10-K for its fiscal year ended March 31, 2023. In the opinion of the Company, all adjustments, including normal recurring adjustments necessary to present fairly the financial position of the Company, as of December 31, 2023, and the results of its operations and cash flows for the three and nine months then ended have been included. The results of operations for the interim period are not necessarily indicative of the results for the full year ending March 31, 2024. The Company had a September 30 fiscal year end. Subsequent to the Agreement with ABTI Pharma, the Company has changed its year end from September 30 to March 31. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates. Cash and Equivalents For purposes of the statement of cash flows, the Company considers highly liquid financial instruments purchased with a maturity of three months or less to be cash equivalents. Fair Value of Financial Instruments Alterola’s financial instruments consist of cash and equivalents, accrued expenses, accrued interest and notes payable. The carrying amount of these financial instruments approximates fair value (“FV”) due either to length of maturity or interest rates that approximate prevailing market rates unless otherwise disclosed in these financial statements. FV is defined as the price that would be received upon sale of an asset or paid upon transfer of a liability in an orderly transaction between market participants at the measurement date and in the principal or most advantageous market for that asset or liability. The FV should be calculated based on assumptions that market participants would use in pricing the asset or liability, not on assumptions specific to the entity. In addition, the FV of liabilities should include consideration of non-performance risk including our own credit risk. ALTEROLA BIOTECH, INC. NOTES TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2023 NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED) In addition to defining FV, the disclosure requirements around FV establish a FV hierarchy for valuation inputs which is expanded. The hierarchy prioritizes the inputs into three levels based on the extent to which inputs used in measuring FV are observable in the market. Each FV measurement is reported in one of the three levels which is determined by the lowest level input that is significant to the FV measurement in its entirety. These levels are: Level 1 – inputs are based upon unadjusted quoted prices for identical instruments traded in active markets. Level 2 – inputs are based upon significant observable inputs other than quoted prices included in Level 1, such as quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 – inputs are generally unobservable and typically reflect management’s estimates of assumptions that market participants would use in pricing the asset or liability. The FV are therefore determined using model-based techniques that include option pricing models, discounted cash flow models, and similar techniques. The carrying value of the Company’s financial assets and liabilities which consist of cash, accounts payable and accrued liabilities, and notes payable are valued using level 1 inputs. The Company believes that the recorded values approximate their FV due to the short maturity of such instruments. Unless otherwise noted, it is management’s opinion that the Company is not exposed to significant interest, exchange or credit risks arising from these financial instruments. Income Taxes Income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized. Foreign Currency Translation The financial statements are presented in US Dollars. Transactions with foreign subsidiaries where US dollars are not the functional currency will be recorded in accordance with Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 830 Foreign Currency Transaction Comprehensive Income Revenue Recognition On January 1, 2018, the Company adopted ASC Topic 606, Revenue from Contracts with Customers ("ASC 606"), using the modified retrospective method applied to those contracts which were not completed as of January 1, 2018. Results for reporting periods beginning after January 1, 2018 are presented under ASC 606, while prior period amounts are not adjusted and continue to be reported in accordance with our historic accounting under ASC 605. As of and for the year ended December 31, 2022, the financial statements were not materially impacted as a result of the application of Topic 606 compared to Topic 605. ALTEROLA BIOTECH, INC. NOTES TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2023 NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED) Loss Per Common Share Basic loss per share is calculated using the weighted-average number of common shares outstanding during each reporting period. Diluted loss per share includes potentially dilutive securities such as outstanding options and warrants, using various methods such as the treasury stock or modified treasury stock method in the determination of dilutive shares outstanding during each reporting period. The Company does not have any potentially dilutive instruments. Stock-Based Compensation Stock-based compensation is accounted for at FV in accordance with ASC Topic 718. To date, the Company has not adopted a stock option plan and has not granted any stock options Research and development We engage in a variety of research and development activities to develop our technologies and work toward development of a saleable product. When it is determined that the research and development products we are creating have reached a point where saleable products are possible, these amounts are capitalized. As of December 31, 2023 and March 31 ,2023 there are no capitalized research and development costs. The research and development costs incurred by the company relate to the following: • Licenses for patent and know-how ( Nano 4 M) - this relates to the company’s formulation of Active Pharmaceutical Ingredients ( API) for its lead pharmaceutical programs. • Protein Technologies Ltd – this relates to the company’s research into production of cannabinoids by biosynthesis (as opposed to botanical production by growing plants). The company has genetically modified an organism to produce cannabinoids by fermentation ( similar to methodology used for the production of antibiotics) • Apex Molecular Ltd.- the company has a number of pharmaceutical development programs using both novel and natural molecules. The Company employs third party chemistry / contract, manufacturing companies such as Apex Molecular Ltd. to synthesize and purify these compounds for their pharmaceutical development programs. • Acquisition of intellectual property from Alinova Biosciences Ltd. • Continued patent prosecution and internationalization of company intellectual property. • Staff costs and consultancy costs relating to R & D. Other Intangible Assets We have recorded the assets acquired as part of the C2 Wellness acquisition as indefinite lived Intangible assets. Indefinite life intangible assets recorded are not amortized and, as a result, are assessed for impairment at least annually, using either a qualitative or quantitative process. We performed this annual assessment as of March 31, 2023, noting no factors indicating possible impairment of intangible assets recognized. Risks and Uncertainties On January 30, 2020, the World Health Organization declared the coronavirus outbreak a “Public Health Emergency of International Concern” and on March 10, 2020, declared it to be a pandemic. Actions taken around the world to help mitigate the spread of the coronavirus include restrictions on travel, and quarantines in certain areas, and forced closures for certain types of public places and business. The Coronavirus and actions taken to mitigate it have had and are expected to have an adverse impact on the economies and financial markets of many countries, including the geographical area in which the Company plans to operate. Recent Accounting Pronouncements Alterola does not expect the adoption of recently issued accounting pronouncements to have a significant impact on the Company’s results of operations, financial position or cash flow. ALTEROLA BIOTECH, INC. NOTES TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2023

NOTE 3 _ ACCRUED EXPENSES

NOTE 3 – ACCRUED EXPENSES	9 Months Ended
NOTE 3 – ACCRUED EXPENSES	Dec. 31, 2023
Payables and Accruals [Abstract]
NOTE 3 – ACCRUED EXPENSES	NOTE 3 – ACCRUED EXPENSES Accrued expenses consisted of the following at December 31, 2023 and March 31, 2023 December 31, 2023 March 31,2023 Audit fees $ — $ 15,000 Accounting 7,407 7,407 Research and development 9,433 9,433 General and administrative 106,014 115,821 Legal fees and transfer agent 187,668 107,203 Total Accrued Expenses $ 310,522 $ 254,864

NOTE 4 _ CAPITAL STOCK

NOTE 4 – CAPITAL STOCK	9 Months Ended
NOTE 4 – CAPITAL STOCK	Dec. 31, 2023
Equity [Abstract]
NOTE 4 – CAPITAL STOCK	NOTE 4 – CAPITAL STOCK The Company has 2,000,000,000 $0.001 10,000,000 $0.001 On August 11, 2021, the Company issued 15,000,000 warrants to purchase common stock at $0.64 per share. The warrants were issued with a 5 year term. The warrants exercise price includes a declining scale with the stock price. As of December 31, 2022, the warrants were exercisable at $0.001 per share and the total potential impact on the financial statements of the exercise of the warrants was approximately $1 million dollars . The warrants were exercised on June 13, 2023 (see below). The total potential impact on the financial statements of the exercise of the warrants was approximately $13,500 During September 2021 , the Company received an investment for £100,000 Sterling (or $136,721 ) in exchange for a subscription for 280,000 280,000 On October 29, 2021, the Company issued 7,500,000 $2,399,250 As pursuant to the asset purchase agreement dated November 9, 2021, the Company acquired certain intellectual property rights of C2 Wellness Corp. In exchanges for the assets acquired, the Company issued 24,000,000 shares of common stock valued at $0.50 per share. The intellectual property rights acquired are recorded as intangible assets as of December 31, 2021 for $12,000,000 . On December 21, 2021, the company issued 520,000 $130,000 On February 8, 2022, the company issued 333,333 $50,000 $0.15 On or about March 3, 2022, the Company issued 16,000,000 $3,360,000 On April 5, 2022, the company issued 384,615 $50,000 $0.13 On April 29, 2022, the Company issued 1,500,000 $0.214 $321,000 On May 2, 2022, the Company issued 280,000 $136,721 $0.50 On May 4, 2022, we issued 2,250,000 ALTEROLA BIOTECH, INC. NOTES TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2023 NOTE 4 – CAPITAL STOCK (CONTINUED) On June 6, 2023, the Company reclaimed 44,064,000 On June 13, 2023, we issued 13,500,000 15,000,000 On June 13, 2023, we issued 476,000 On June 13, 2023, we issued 5,000,000 June 13, 2023, we issued 5,999,900 June 13, 2023, we issued 10,088,100 On June 14, 2023, we issued 9,000,000 On September 8, 2023, the Company entered into an Agreement to Return Assets and Shares with C2 Wellness Corp. As part of the agreement, the company received 29,015,993 shares of ABTI stock (24,000,000 shares originally issued and 5,015,996 shares additionally issued) and sold all assets related to the acquisition, resulting in a write-off of $12,000,000 in intangibles. On October 16, 2023, the Company issued 587,499,996 $406,575 On December 21, 2023, the Company issued 17,131,001 $61,672 The Company has 1,382,662,952 807,047,948 no 807,047,948 802,913,333

NOTE 5 _ NOTES PAYABLE

NOTE 5 – NOTES PAYABLE	9 Months Ended
NOTE 5 – NOTES PAYABLE	Dec. 31, 2023
Debt Disclosure [Abstract]
NOTE 5 – NOTES PAYABLE	NOTE 5 – NOTES PAYABLE On August 1, 2022, the Company issued a note payable for 90 days $75,000 2,250,000 $75,000 ALTEROLA BIOTECH, INC. NOTES TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2023

NOTE 6 _ RELATED PARTY TRANSACT

NOTE 6 – RELATED PARTY TRANSACTIONS	9 Months Ended
NOTE 6 – RELATED PARTY TRANSACTIONS	Dec. 31, 2023
Related Party Transactions [Abstract]
NOTE 6 – RELATED PARTY TRANSACTIONS	NOTE 6 – RELATED PARTY TRANSACTIONS Alterola neither owns nor leases any real or personal property. An officer has provided office space as an arms length transaction with rental at commercial rates. There is no obligation for the officer to continue this arrangement. Such costs are immaterial to the financial statements and accordingly are not reflected herein. The officers and directors are involved in other business activities and most likely will become involved in other business activities in the future. During the period ended December 31, 2023, a shareholder made advances to the company to fund operating expenses in the amount of $244,061 These advances are non – interest bearing and have no specified terms of repayment

NOTE 7 _ SUBSEQUENT EVENTS

NOTE 7 – SUBSEQUENT EVENTS	9 Months Ended
NOTE 7 – SUBSEQUENT EVENTS	Dec. 31, 2023
Subsequent Events [Abstract]
NOTE 7 – SUBSEQUENT EVENTS	NOTE 7 – SUBSEQUENT EVENTS In accordance with ASC Topic 855-10, the Company analyzed its operations subsequent to December 31, 2023 to the date these financial statements were issued, and determined it does not have any material subsequent events to disclose in these financial statements, except as noted below.

NOTE 2 _ SUMMARY OF SIGNIFICA_2

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation These unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”). They include the accounts of Alterola and its wholly owned subsidiaries ABTI Pharma, Phytotherapeutix Ltd and Ferven Ltd.. All material intercompany transactions and balances have been eliminated. These financial statements and the notes attached hereto should be read in conjunction with the financial statements and notes included in the Company’s 10-K for its fiscal year ended March 31, 2023. In the opinion of the Company, all adjustments, including normal recurring adjustments necessary to present fairly the financial position of the Company, as of December 31, 2023, and the results of its operations and cash flows for the three and nine months then ended have been included. The results of operations for the interim period are not necessarily indicative of the results for the full year ending March 31, 2024. The Company had a September 30 fiscal year end. Subsequent to the Agreement with ABTI Pharma, the Company has changed its year end from September 30 to March 31.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Cash and Equivalents	Cash and Equivalents For purposes of the statement of cash flows, the Company considers highly liquid financial instruments purchased with a maturity of three months or less to be cash equivalents.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Alterola’s financial instruments consist of cash and equivalents, accrued expenses, accrued interest and notes payable. The carrying amount of these financial instruments approximates fair value (“FV”) due either to length of maturity or interest rates that approximate prevailing market rates unless otherwise disclosed in these financial statements. FV is defined as the price that would be received upon sale of an asset or paid upon transfer of a liability in an orderly transaction between market participants at the measurement date and in the principal or most advantageous market for that asset or liability. The FV should be calculated based on assumptions that market participants would use in pricing the asset or liability, not on assumptions specific to the entity. In addition, the FV of liabilities should include consideration of non-performance risk including our own credit risk. ALTEROLA BIOTECH, INC. NOTES TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2023 NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED) In addition to defining FV, the disclosure requirements around FV establish a FV hierarchy for valuation inputs which is expanded. The hierarchy prioritizes the inputs into three levels based on the extent to which inputs used in measuring FV are observable in the market. Each FV measurement is reported in one of the three levels which is determined by the lowest level input that is significant to the FV measurement in its entirety. These levels are: Level 1 – inputs are based upon unadjusted quoted prices for identical instruments traded in active markets. Level 2 – inputs are based upon significant observable inputs other than quoted prices included in Level 1, such as quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 – inputs are generally unobservable and typically reflect management’s estimates of assumptions that market participants would use in pricing the asset or liability. The FV are therefore determined using model-based techniques that include option pricing models, discounted cash flow models, and similar techniques. The carrying value of the Company’s financial assets and liabilities which consist of cash, accounts payable and accrued liabilities, and notes payable are valued using level 1 inputs. The Company believes that the recorded values approximate their FV due to the short maturity of such instruments. Unless otherwise noted, it is management’s opinion that the Company is not exposed to significant interest, exchange or credit risks arising from these financial instruments.
Income Taxes	Income Taxes Income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized.
Foreign Currency Translation	Foreign Currency Translation The financial statements are presented in US Dollars. Transactions with foreign subsidiaries where US dollars are not the functional currency will be recorded in accordance with Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 830 Foreign Currency Transaction Comprehensive Income
Revenue Recognition	Revenue Recognition On January 1, 2018, the Company adopted ASC Topic 606, Revenue from Contracts with Customers ("ASC 606"), using the modified retrospective method applied to those contracts which were not completed as of January 1, 2018. Results for reporting periods beginning after January 1, 2018 are presented under ASC 606, while prior period amounts are not adjusted and continue to be reported in accordance with our historic accounting under ASC 605. As of and for the year ended December 31, 2022, the financial statements were not materially impacted as a result of the application of Topic 606 compared to Topic 605. ALTEROLA BIOTECH, INC. NOTES TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2023 NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)
Loss Per Common Share	Loss Per Common Share Basic loss per share is calculated using the weighted-average number of common shares outstanding during each reporting period. Diluted loss per share includes potentially dilutive securities such as outstanding options and warrants, using various methods such as the treasury stock or modified treasury stock method in the determination of dilutive shares outstanding during each reporting period. The Company does not have any potentially dilutive instruments.
Stock-Based Compensation	Stock-Based Compensation Stock-based compensation is accounted for at FV in accordance with ASC Topic 718. To date, the Company has not adopted a stock option plan and has not granted any stock options
Research and development	Research and development We engage in a variety of research and development activities to develop our technologies and work toward development of a saleable product. When it is determined that the research and development products we are creating have reached a point where saleable products are possible, these amounts are capitalized. As of December 31, 2023 and March 31 ,2023 there are no capitalized research and development costs. The research and development costs incurred by the company relate to the following: • Licenses for patent and know-how ( Nano 4 M) - this relates to the company’s formulation of Active Pharmaceutical Ingredients ( API) for its lead pharmaceutical programs. • Protein Technologies Ltd – this relates to the company’s research into production of cannabinoids by biosynthesis (as opposed to botanical production by growing plants). The company has genetically modified an organism to produce cannabinoids by fermentation ( similar to methodology used for the production of antibiotics) • Apex Molecular Ltd.- the company has a number of pharmaceutical development programs using both novel and natural molecules. The Company employs third party chemistry / contract, manufacturing companies such as Apex Molecular Ltd. to synthesize and purify these compounds for their pharmaceutical development programs. • Acquisition of intellectual property from Alinova Biosciences Ltd. • Continued patent prosecution and internationalization of company intellectual property. • Staff costs and consultancy costs relating to R & D.
Other Intangible Assets	Other Intangible Assets We have recorded the assets acquired as part of the C2 Wellness acquisition as indefinite lived Intangible assets. Indefinite life intangible assets recorded are not amortized and, as a result, are assessed for impairment at least annually, using either a qualitative or quantitative process. We performed this annual assessment as of March 31, 2023, noting no factors indicating possible impairment of intangible assets recognized.
Risks and Uncertainties	Risks and Uncertainties On January 30, 2020, the World Health Organization declared the coronavirus outbreak a “Public Health Emergency of International Concern” and on March 10, 2020, declared it to be a pandemic. Actions taken around the world to help mitigate the spread of the coronavirus include restrictions on travel, and quarantines in certain areas, and forced closures for certain types of public places and business. The Coronavirus and actions taken to mitigate it have had and are expected to have an adverse impact on the economies and financial markets of many countries, including the geographical area in which the Company plans to operate.
Recent Accounting Pronouncements	Recent Accounting Pronouncements Alterola does not expect the adoption of recently issued accounting pronouncements to have a significant impact on the Company’s results of operations, financial position or cash flow.

NOTE 3 _ ACCRUED EXPENSES (Tabl

NOTE 3 – ACCRUED EXPENSES (Tables)	9 Months Ended
NOTE 3 – ACCRUED EXPENSES (Tables)	Dec. 31, 2023
Payables and Accruals [Abstract]
NOTE 3 - ACCRUED EXPENSES - Schedule of Accrued Expenses	December 31, 2023 March 31,2023 Audit fees $ — $ 15,000 Accounting 7,407 7,407 Research and development 9,433 9,433 General and administrative 106,014 115,821 Legal fees and transfer agent 187,668 107,203 Total Accrued Expenses $ 310,522 $ 254,864

NOTE 1 _ NATURE OF BUSINESS, _2

NOTE 1 – NATURE OF BUSINESS, LIQUIDITY & GOING CONCERN (Details Narrative) - USD ($)			1 Months Ended		168 Months Ended
	Sep. 08, 2023	Jul. 05, 2023	Jan. 29, 2021	May 03, 2010	Sep. 30, 2023	Dec. 31, 2023	Mar. 31, 2023	May 28, 2021
Liabilities						$ 1,358,424	$ 2,281,416	$ 389,721
Banking Regulation, Total Capital, Actual						$ 1,160,035
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest					$ 11,946,656
Patent P T X [Member]
Stock Issued During Period, Shares, Acquisitions		5,000,000
Acquisition Costs, Period Cost		$ 35,000
Director
Stock Issued During Period, Shares, Acquisitions				55,000,000
Consulting Services
Stock Issued During Period, Shares, Acquisitions			600,000,000
C 2 Wellness Agreement Return Assets [Member]
Stock Repurchased During Period, Shares	29,015,993

NOTE 3 - ACCRUED EXPENSES - Sch

NOTE 3 - ACCRUED EXPENSES - Schedule of Accrued Expenses (Details) - USD ($)	Dec. 31, 2023	Mar. 31, 2023
Interim Period, Costs Not Allocable [Line Items]
Total Accrued Expenses	$ 310,522	$ 254,864
Audit Fees [Member]
Interim Period, Costs Not Allocable [Line Items]
Accrued Professional Fees, Current		15,000
Accounting [Member]
Interim Period, Costs Not Allocable [Line Items]
Accrued Professional Fees, Current	7,407	7,407
Research And Development [Member]
Interim Period, Costs Not Allocable [Line Items]
Accrued Professional Fees, Current	9,433	9,433
General and Administrative Expense [Member]
Interim Period, Costs Not Allocable [Line Items]
Accrued Professional Fees, Current	106,014	115,821
Legal And Transfer Agent [Member]
Interim Period, Costs Not Allocable [Line Items]
Accrued Professional Fees, Current	$ 187,668	$ 107,203

NOTE 4 _ CAPITAL STOCK (Details

NOTE 4 – CAPITAL STOCK (Details Narrative) - USD ($)

1 Months Ended

9 Months Ended

Dec. 21, 2023

Oct. 16, 2023

Sep. 08, 2023

Jun. 14, 2023

Jun. 13, 2023

Jun. 06, 2023

May 04, 2022

May 02, 2022

Apr. 29, 2022

Apr. 05, 2022

Mar. 03, 2022

Dec. 21, 2021

Nov. 09, 2021

Oct. 29, 2021

Aug. 11, 2021

Sep. 30, 2021

Dec. 31, 2023

Dec. 31, 2022

Mar. 31, 2023

Mar. 31, 2022

Dec. 31, 2021

Accumulated Other Comprehensive Income (Loss) [Line Items]

Common Stock, Shares Authorized

2,000,000,000

Common Stock, Par or Stated Value Per Share

$ 0.001

Preferred Stock, Shares Authorized

10,000,000

Preferred Stock, Par or Stated Value Per Share

$ 0.001

Stock Issued During Period, Shares, Issued for Services

7,500,000

Stock Issued During Period, Value, Issued for Services

$ 305,672

$ 321,000

Intangible Assets, Current

$ 12,139,779

$ 12,000,000

Stock Issued During Period, Value, Other

157,339

Stock Issued During Period, Shares, Treasury Stock Reissued

44,064,000

Stock Issued During Period, Value, Conversion of Convertible Securities

Contract with Customer, Asset, Allowance for Credit Loss, Writeoff

12,000,000

[custom:StockIssuedDuringPeriodValueConversionOfDebt]

$ 587,499,996

$ 2,350,000

[custom:LossOnExchangeOfSharesForDebt]

$ 406,575

Common Stock, Shares, Issued

1,382,662,952

807,047,948

802,913,333

Common Stock, Shares, Outstanding

1,382,662,952

807,047,948

802,913,333

Preferred Stock, Shares Issued

Preferred Stock, Shares Outstanding

Warrant Shares [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Stock Issued During Period, Shares, Other

15,000,000

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 0.64

Warrants and Rights Outstanding, Term

5 years

Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price

$ 0.001

Unusual Risk or Uncertainty, Impact

the
total potential impact on the financial statements of the exercise of the warrants was approximately $1 million dollars

[custom:PotentialFinancialImpactOfWarrantExercise-0]

$ 13,500

Consultancy Agreement [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Proceeds from Issuance of Common Stock

$ 136,721

Stock Issued During Period, Shares, Issued for Services

1,500,000

Stock Issued During Period, Value, Issued for Services

$ 321,000

Shares Issued, Price Per Share

$ 0.214

Sale of Stock, Price Per Share

$ 0.50

Subscription [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Stock Issued During Period, Shares, Other

280,000

Investor Issuance Three [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Stock Issued During Period, Shares, Other

280,000

384,615

Shares Issued, Price Per Share

$ 0.13

Stock Issued During Period, Value, Other

$ 50,000

E M C 2 Capital [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Stock Issued During Period, Value, Issued for Services

$ 2,399,250

A P A Nov 9 [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Stock Issued During Period, Shares, Acquisitions

24,000,000

Shares Issued, Price Per Share

$ 0.50

Investor Issuance Two [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Stock Issued During Period, Shares, Other

333,333

520,000

Shares Issued, Price Per Share

$ 0.15

Stock Issued During Period, Value, Other

$ 50,000

$ 130,000

Consulting Agreement [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Stock Issued During Period, Shares, Issued for Services

16,000,000

Stock Issued During Period, Value, Issued for Services

$ 3,360,000

Director Issuance [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Stock Issued During Period, Shares, Employee Benefit Plan

2,250,000

E M C 2 Capital L L C [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Stock Issued During Period, Value, Conversion of Convertible Securities

$ 13,500,000

Stock Redeemed or Called During Period, Shares

15,000,000

Alison Burgess [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Stock Issued During Period, Shares, Other

476,000

Alinova Biosciences [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Stock Issued During Period, Shares, Acquisitions

5,000,000

Long Eight Limited [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Stock Issued During Period, Shares, Issued for Services

5,999,900

Warren Law Group [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Stock Issued During Period, Shares, Issued for Services

10,088,100

Directors [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Stock Issued During Period, Shares, Employee Benefit Plan

9,000,000

C 2 Wellness Agreement Return Assets [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Stock Repurchased During Period, Shares

29,015,993

Dec 2023 Services [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Stock Issued During Period, Shares, Issued for Services

17,131,001

Stock Issued During Period, Value, Issued for Services

$ 61,672

NOTE 5 _ NOTES PAYABLE (Details

NOTE 5 – NOTES PAYABLE (Details Narrative) - USD ($)	17 Months Ended
NOTE 5 – NOTES PAYABLE (Details Narrative) - USD ($)	Dec. 23, 2023	Dec. 31, 2023	Mar. 31, 2023	Aug. 01, 2022	Jul. 18, 2022
Debt Disclosure [Abstract]
Loan, Held-for-Sale, Term				90 days
Loans Payable, Current		$ 244,061	$ 1,260,434		$ 75,000
Common Stock, Shares Subscribed but Unissued				2,250,000
Repayments of Long-Term Loans from Vendors	$ 75,000

NOTE 6 _ RELATED PARTY TRANSA_2

NOTE 6 – RELATED PARTY TRANSACTIONS (Details Narrative)	9 Months Ended
NOTE 6 – RELATED PARTY TRANSACTIONS (Details Narrative)	Dec. 31, 2023 USD ($)
Related Party Transaction [Line Items]
[custom:ShareholderAdvances]	$ 244,061
Shareholder Advances [Member]
Related Party Transaction [Line Items]
Debt Instrument, Description	These advances are non – interest bearing and have no specified terms of repayment